Benchmark reissued their buy rating on shares of Natus Medical (NASDAQ:BABY) in a research note published on Tuesday morning, Marketbeat reports. Benchmark currently has a $49.00 price target on the medical equipment provider’s stock, down from their prior price target of $55.00.
Other research analysts have also recently issued reports about the company. Zacks Investment Research raised Natus Medical from a hold rating to a buy rating and set a $45.00 price target for the company in a report on Tuesday, October 24th. William Blair cut Natus Medical from an outperform rating to a market perform rating in a report on Monday, January 8th. Finally, BidaskClub cut Natus Medical from a hold rating to a sell rating in a report on Saturday, December 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. Natus Medical has an average rating of Hold and an average target price of $47.00.
Shares of Natus Medical (NASDAQ:BABY) traded down $0.30 during midday trading on Tuesday, hitting $28.25. The company’s stock had a trading volume of 362,985 shares, compared to its average volume of 1,013,746. The company has a market capitalization of $880.10, a PE ratio of -470.83 and a beta of 0.84. Natus Medical has a 12 month low of $28.05 and a 12 month high of $43.60. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21.
In related news, Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in BABY. Benjamin F. Edwards & Company Inc. increased its position in Natus Medical by 2,085.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after purchasing an additional 2,607 shares during the period. Riverhead Capital Management LLC increased its position in Natus Medical by 90.9% in the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after purchasing an additional 1,364 shares during the period. SG Americas Securities LLC acquired a new stake in Natus Medical in the third quarter worth about $138,000. Victory Capital Management Inc. increased its position in Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after purchasing an additional 560 shares during the period. Finally, Flinton Capital Management LLC increased its position in Natus Medical by 82.0% in the second quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after purchasing an additional 1,700 shares during the period. 99.87% of the stock is owned by institutional investors and hedge funds.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.